Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Trading Update

25 May 2018 07:00

RNS Number : 2587P
Surgical Innovations Group PLC
25 May 2018
 

 

Surgical Innovations Group plc

("SI", "the Company" or the "Group")

 

Trading Update

 

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical technology for minimally invasive surgery, provides an update on current trading and the outlook for the year ending 31 December 2018.

 

The Company is experiencing delays in the supply of products for its UK distribution business, Elemental Healthcare Limited ("Elemental"), sourced from Meccellis Biotech SA ("Meccellis").

 

Since 2015, Elemental has been the exclusive UK distributor of a range of biological matrices under the brand "Cellis", which are used in complex abdominal wall and breast reconstruction procedures. During 2017, Meccellis began to undertake a transition to a new notified body for European regulatory approval, including the recertification of its existing products, and the certification of new products.

 

This transition has encountered delays which were not anticipated until very late in the process, and despite mitigating actions taken by both Meccellis and Elemental to ensure continuity of supply, it is apparent that product availability will have a continuing impact on revenues of SI Group in the current financial year. The SI Board has determined that it would be prudent to exclude revenues from Cellis products from current year expectations until such time as there is certainty regarding the availability of current and new products in this range following regulatory approval.

 

This has the effect of reducing revenue expectations for the current financial year by approximately 10%, or £1.25m, on the cautious assumption that sales do not resume in the current year. Revenues from other segments of SI Group activities, comprising the worldwide sale of SI brand products manufactured in the UK and the design and manufacture of OEM products, are unaffected. With the assumption of reduced revenues, the Board anticipates that profit before tax will show modest growth over that reported for the financial year ended 31 December 2017.

 

Further market updates will be provided as this situation develops, and a further trading update will be presented on the day of the Annual General Meeting which will be held at 3.00 p.m. on 26 June 2018 at WH Ireland Limited, 24 Martin Lane, London EC4R 0DR.

 

This announcement includes inside information as defined by Article 7 of the Market Abuse Regulation No. 596/2014 and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

 

For further information please contact:

 

Surgical Innovations Group plc

www.sigroupplc.com

Nigel Rogers, Executive Chairman

Tel: 0113 230 7597

Melanie Ross, COO & CFO

WH Ireland Limited (NOMAD & Broker)

Tel: 0113 394 6600

Tim Feather

Alex Bond

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Helen Cresswell

Mob: 07841 917 679

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLLFVREAISFIT
Date   Source Headline
10th Jan 20137:00 amRNSDirectors shareholding
18th Dec 20129:24 amRNSDirectors' dealings and issue of equity
18th Dec 20127:00 amRNSAppointments to the Clinical Advisory Board
29th Oct 20127:00 amRNSFirst PretzelFlex® orders shipped to CareFusion
11th Oct 20127:00 amRNSSuccessful exhibition at ISHA in the US
18th Sep 20127:00 amRNSHalf Yearly Report
4th Sep 20127:00 amRNSNotice of Results
30th Aug 20122:14 pmRNSHolding(s) in Company
26th Jun 20127:00 amRNSGrant of options
19th Jun 20123:33 pmRNSResult of AGM
19th Jun 20127:00 amRNSAGM Statement
18th Jun 20127:00 amRNSOEM distribution agreement with CareFusion
31st May 20127:00 amRNSUK distribution agreement
25th May 201211:58 amRNSDirectorate Change
22nd May 20127:00 amRNSPublication of Annual Report and Notice of AGM
1st May 20127:00 amRNSInvestor site visit
24th Apr 20127:00 amRNSFinal Results
20th Apr 20127:00 amRNSNotice of Results
15th Mar 20127:00 amRNSFDA 510(k) approval for reusable PretzelFlexT
23rd Feb 20124:54 pmRNSHolding(s) in Company
17th Feb 20124:36 pmRNSDirector/PDMR Shareholding
14th Feb 20125:49 pmRNSIssue of Equity
1st Feb 20127:00 amRNSRe: US contract and FDA approval
23rd Jan 20127:01 amRNSTrading Statement
2nd Dec 20117:00 amRNSInvestor Site Visit
3rd Nov 20117:00 amRNSIssue of Equity
1st Nov 20117:00 amRNSConfirmation of successful RGF bid
21st Sep 20114:49 pmRNSIssue of Equity
14th Sep 20117:00 amRNSHalf Yearly Report
1st Sep 20115:23 pmRNSHolding(s) in Company
1st Sep 20117:00 amRNSRe Agreement
1st Sep 20117:00 amRNSAgreement with Surgical Innovations Group
24th Aug 20117:00 amRNSNotice of Results
22nd Jul 20117:00 amRNSRe Agreement
20th Jun 20112:42 pmRNSResult of AGM
20th Jun 20117:00 amRNSAGM Statement
13th Jun 20115:08 pmRNSHolding(s) in Company
11th May 20115:12 pmRNSIssue of Equity
3rd May 20114:05 pmRNSIssue of Equity
26th Apr 20114:34 pmRNSDirector/PDMR Shareholding
21st Apr 201111:47 amRNSHolding(s) in Company
19th Apr 20117:00 amRNSFinal Results
28th Mar 201112:04 pmRNSHolding(s) in Company
24th Mar 201112:17 pmRNSHolding(s) in Company
24th Feb 20113:40 pmRNSHolding(s) in Company
15th Feb 20114:45 pmRNSExercise of Options
14th Feb 20117:00 amRNSRe Contract
14th Jan 201110:08 amRNSTrading Statement
1st Dec 20107:00 amRNSChange of Adviser
29th Oct 201012:11 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.